RT Book, Section A1 Granwehr, Bruno P. A1 Chemaly, Roy F. A1 Kontoyiannis, Dimitrios P. A2 Kantarjian, Hagop M. A2 Wolff, Robert A. SR Print(0) ID 1126746113 T1 Fungal and Viral Infections in Cancer Patients T2 The MD Anderson Manual of Medical Oncology, 3e YR 2016 FD 2016 PB McGraw-Hill Medical PP New York, NY SN 9780071847940 LK hemonc.mhmedical.com/content.aspx?aid=1126746113 RD 2021/02/25 AB Fungal and viral infections remain a significant cause of morbidity and mortality in patients with cancer. Modern management of infections in cancer requires knowledge of the epidemiology, pathogenesis, treatment, and prevention of such infections. Fungal infections range from nosocomial infections with Candida spp to endemic fungi acquired outside the hospital, such as Histoplasma capsulatum. Opportunistic fungi, especially molds, have emerged as a leading cause of death in patients with leukemia or hematopoietic stem cell transplant (HSCT) (1). Viral infections such as varicella zoster virus (VZV), herpes simplex virus (HSV), or cytomegalovirus (CMV), have been associated with increased morbidity and mortality in patients with cancer, including patients with multiple myeloma or chronic lymphocytic leukemia (CLL), and in HSCT recipients (2,3,4,5). Respiratory viruses, such as respiratory syncytial (RSV), adenovirus, and influenza, are increasingly recognized as significant pathogens in patients with cancer, particularly as molecular diagnostic methods improve. In addition, viruses such as novel influenza H1N1, West Nile virus, bocaviruses, and noroviruses have emerged as newly recognized pathogens in patients with cancer.